title: Ibopamine kinetics after a single oral dose in patients with congestive heart failure.
abstract: The kinetics of ibopamine, the 3,4-diisobutyryl ester of N-methyldopamine (epinine), was assessed in 27 patients with congestive heart failure (CHF) and 8 healthy normal subjects (NS). Nine patients were in functional class IV according to the NYHA definition, 9 in class III and 9 in class II. Ibopamine was administered at a single oral dose of 100 mg. Epinine, both free and total (mainly conjugated), plasma concentrations and urinary recoveries of total epinine, HVA and DOPAC were studied. The results showed that ibopamine kinetics is not substantially different in CHF patients and in NS. In both groups the absorption of the drug was equally prompt and elevated. Mean Cmax, tmax and AUC infinity values of total epinine in CHF patients did not differ significantly from those in NS. In CHF patients t 1/2 of total epinine was significantly higher than in NS (4.1 +/- 0.2 h vs 3.1 +/- 0.2 h, mean +/- SE). Mean Cmax, tmax, AUCt and MRT values of free epinine in CHF patients were not significantly different from those in NS. The urinary recovery of the 3 metabolites considered together was comparable in CHF patients and in NS. The mean +/- SE total urinary recoveries in the 24 h after dosing, expressed as percentages of the administered dose, were 60 +/- 3 in CHF patients and 69 +/- 4 in NS. Conjugated epinine in urine was found to be constituted by 3-O-sulfate (84%) and 4-O-sulfate (16%).
authors.affiliation: Department of Medicine, IOPM, Milano, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Azzollini
authors.forename: G
authors.initials: G
authors.lastname: Cattò
authors.forename: G
authors.initials: G
authors.lastname: Iacuitti
authors.forename: G
authors.initials: G
authors.lastname: Pelosi
authors.forename: M
authors.initials: M
authors.lastname: Picca
authors.forename: F
authors.initials: F
authors.lastname: Pocchiari
authors.forename: R
authors.initials: R
authors.lastname: Pataccini
authors.forename: P
authors.initials: P
authors.lastname: Castelnovo
authors.forename: A
authors.initials: A
authors.lastname: Longo
authors.forename: G P
authors.initials: GP
authors.lastname: Ventresca
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002851:Chromatography, High Pressure Liquid; D003846:Deoxyepinephrine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D004298:Dopamine / Q000031:analogs & derivatives*; D005260:Female; D006207:Half-Life; D006333:Heart Failure / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*
chemical_list: D014665:Vasodilator Agents; C023487:ibopamine; D003846:Deoxyepinephrine; D004298:Dopamine